OCA
INZY

Octagon Capital Advisors’s Inozyme Pharma INZY Stock Holding History

Octagon Capital Advisors’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-400,000
Closed -$1.7M – 60
2023
Q4 		$1.7M Sell
400,000
-900,000
-69% -$3.2M 0.27% 28
2023
Q3 		$5.46M Buy
1,300,000
+1,250,298
+2,516% +$6.36M 0.84% 25
2023
Q2 		$277K Buy
+49,702
New +$294K 0.04% 40

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Octagon Capital Advisors's INZY Position: Q1 2024 in Review

Octagon Capital Advisors sold out of Inozyme Pharma (INZY) in Q1 2024, closing a stake of 400,000 shares — an estimated $1.7M sold.

Octagon Capital Advisors first reported a position in INZY in Q2 2023 and held it in 3 quarters. The position peaked at $5.46M in Q3 2023. 89 funds tracked by Wall St. Rank hold INZY as of Q1 2024.

  • Octagon Capital Advisors reported no remaining Inozyme Pharma position as of Q1 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 400,000 Inozyme Pharma shares in Q1 2024, an estimated $1.7M.
  • Octagon Capital Advisors first reported a position in Inozyme Pharma in Q2 2023 and held it in 3 quarters.
  • Octagon Capital Advisors's Inozyme Pharma position peaked at $5.46M in Q3 2023.
  • 89 funds tracked by Wall St. Rank held Inozyme Pharma as of Q1 2024.

Based on Octagon Capital Advisors's 13F filing for Q1 2024, filed 15 May 2024.